Literature DB >> 4042526

Terazosin kinetics after oral and intravenous doses.

S E Patterson.   

Abstract

Terazosin kinetics were followed in normal subjects after intravenous doses of 0.5, 1.0, and 2.0 mg and oral doses of 1.0 mg. Plasma and urine samples were collected for the first 48 and 24 hours. The samples were analyzed by a sensitive HPLC assay developed in our laboratory. Mean calculated peak plasma levels from the 0.5, 1.0, and 2.0 mg intravenous doses were 25.0, 44.1, and 83.3 ng/ml. After a 1 mg oral dose the mean peak level was 19.6 ng/ml. Data were fit to a two-compartment open model with mean elimination phase t1/2 values of 7.9, 8.9, and 10.1 hours for the ascending intravenous doses and 11.6 hours for the oral dose. Mean 0 to 24-hour urinary recovery after the intravenous doses was 14%, 13%, and 11%. It is concluded that terazosin kinetics are linear after oral and intravenous doses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042526     DOI: 10.1038/clpt.1985.198

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.

Authors:  R F Schäfers; B Fokuhl; A Wasmuth; H Schumacher; K Taguchi; C de Mey; T Philipp; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 2.  Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory.

Authors:  Kaori Ito; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-10-17       Impact factor: 4.335

Review 3.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.

Authors:  J Vincent; W Dachman; T F Blaschke; B B Hoffman
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 5.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.

Authors:  S Titmarsh; J P Monk
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

6.  Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.

Authors:  Dierk Thomas; Anna-Britt Wimmer; Kezhong Wu; Bettina C Hammerling; Eckhard K Ficker; Yuri A Kuryshev; Johann Kiehn; Hugo A Katus; Wolfgang Schoels; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-20       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.